July 24th 2023
According to experts, genomic testing is a key tool impacting treatment decisions for physicians treating patients with non–small cell lung cancer.
May 24th 2023
Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.
February 3rd 2023
In an interview with Targeted Oncology, John Diaz, MD summarized the ovarian cancer treatment paradigm, and discussed the role of genomic testing and novel targets being explored in the space.
October 17th 2022
As we identify more targets...there will probably be more and newer, perhaps even better, therapeutics than we have currently, said Dennis J. Slamon, MD.
August 26th 2022
According to experts, routine biomarker testing has become a standard part of care for several common tumor types.
Study Shows Feasibility of Using Exome Sequencing to Conduct CDCT1 Genetic Condition Screening
Whole-exome sequencing demonstrated the ability to identify genetic conditions in patients for whom clinical guidelines did not require testing.
African Ancestry Among Patients with Colorectal Cancer May Correlate With Fewer Actionable Alterations
At the AACR 2023 Annual Meeting, a presentation revealed that people with colorectal cancer and African ancestry are less likely to be candidates for targeted therapy.
Florida Cancer Specialists & Research Institute Celebrates Addition of Next Generation Genomic Testing Capabilities to Advance Precision Oncology Approach to Patient Care
Florida Cancer Specialists & Research Institute celebrated the addition of genomic testing capabilities at its Next Generation Sequencing laboratory in Fort Myers last week with a ribbon cutting ceremony.
Subtype-Specific Immune Signatures Found in BTC Profiling Data
Specific biliary tract cancer clusters have distinct clinical and biologic features which may provide opportunities for therapeutic development.
Genomic Profiling Program for High-Risk Pediatric Cancer Patients Makes Clinical Impact
A tumor genomic profiling program has shown feasibility and clinical impact for pediatric patients who are high-risk de novo and relapsed/refractory.
AHN Cancer Institute, Illumina to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care
Allegheny Health Network Cancer Institute will be collaborating with Illumina to evaluate the impact of in-house comprehensive genomic profiling to enhance patient care.
AHN Partners With Illumina to Assess Role of Comprehensive Genomic Profiling
Allegheny Health Network and Illumina, Inc. announced a collaborative effort to assess their in-house comprehensive genomic testing to analyze the role of genetic tests in improving cancer care.
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study
Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Novel Testing Modalities Are Poised to Improve Diagnosis and Prognosis
Improving our diagnostic and prognostic testing capabilities is one of the most important and exciting ways to improve how we care for patients with cancer, according to John M. Burke, MD.
ctDNA Is Improving Oncology Care and Should Be Part of the Standard of Care
Many oncologists, including surgeons, medical oncologists, and radiation oncologists, have already started to incorporate ctDNA testing as part of their standard practice to monitor treatment response and aid in the interpretation of equivocal imaging findings and in surveillance for recurrence.
Delays in BRAF Test Results Affect Quality of Care, Therapeutic Options in Melanoma
Barriers to improving BRAF testing turnaround time in patients with melanoma have been identified in a retrospective analysis of real-world data collected in Canada.
Investigators Evaluate ctDNA Assay, Imaging, and CEA Levels as Surveillance Strategies in Resected Colorectal Cancer
Next-Generation Sequencing Applied to the Cancer Landscape
Next-generation sequencing provides oncologists with accurate information in a cost-effective manner, thereby affording treatment options we would not otherwise have.
FDA Approves Olaparib CDx to Detect BRCA in High Risk Early Breast Cancer
The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.
Niraparib Treatment Displays Promising Clinical Activity in mCRPC Regardless of BRCA Status
Findings from the GALAHAD clinical trial highlight the importance of molecular testing to inform treatment and disease management decision for prostate cancer.
Evolving Biomarkers Span Proteomic, Genomic Fields in Multiple Myeloma
There are still a lot of things that are ongoing, and the myeloma field is evolving with new treatments, according to Mark Bustoros, MBBCh.
Genomic Testing Leads to Strides in Targeted Therapy for CRC
With an increase in genomic testing for colorectal cancer, new targeted treatments have also been developed to treat patients with specific disease characteristics.
Multigene Sequencing Used to Choose Matched Targeted Therapy in mBC Show PFS Improvement
A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.
Overcoming Barriers to Genomic Testing in Community Care Settings
Genomic testing has grown in importance as the number of targeted anticancer therapies rises. Early genomic testing can help to guide treatment choices.
Progress Is Being Made Toward Improvements in Biomarker Testing, Turnaround Times for NSCLC
In an interview with Targeted Therapies in Oncology, Nicholas J. Robert, MD, discussed what the results to date of the MYLUNG study mean for patients with non–small cell lung cancer.
New FDA Recognized MSK Database Makes 5600 Mutations Searchable to Researchers
A new database organizes information on driver mutations for researchers.
Roundtable Discussion: Participants Explore Molecular Testing in the Lung Cancer Setting
A 59-year-old man presented with dyspnea on exertion, fatigue, anorexia, and a 5-lb weight loss. He received the diagnosis of stage IVA adenocarcinoma and had an ECOG performance status of 1.
Genetic Testing Capabilities at Florida Cancer Specialists & Research Institute Grow
Florida Cancer Specialists & Research Institute has expanded its molecular testing capabilities at its state-of-the-art Pathology Laboratory in Fort Myers and is providing patients with clinical next-generation sequencing.
Genetic Testing Empowers Better Cancer Care, Prevention, and Early Detection
Today, many community oncology practices routinely employ genetic testing, enabling newly diagnosed patients and their oncologists to make treatment decisions and to formulate preventive strategies based on genetic information.
Roundtable Discussion: Participants Reflect on Sending Blood- Vs Tissue-Based Tests in NSCLC
During a Targeted Oncology Case-Based Roundtable event, Grace K. Dy, MD and 9 other physicians discussed molecular testing for patients with non–small cell lung cancer.
Large NGS Trial Identifies Actionable Alterations in Most Patients With Advanced Cancers
Potentially clinically actionable genomic alterations were identified in a majority of patients with advanced cancers with next-generation sequencing evaluated in a prospective study.
Genetic Testing Informs Treatment Decisions in Melanoma
Novel methods of genetic testing have led to improved detection and better clinical decisions in patients with melanoma, especially in the late-stage setting.
Next-Generation Sequencing Informs Genetic Testing in Breast Cancer
As the understanding of genetic risk factors in breast cancer continues to grow, professional organizations have sought to provide specific recommendations for genetic testing that would prevent overtesting yet still diagnose as many mutations as possible in patients.
FDA Approves CDx for Lorlatinib in ALK-Positive Non–Small Cell Lung Cancer
The FDA has granted approval to the VENTANA ALK CDx Assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who may be eligible for treatment with the recently approved ALK inhibitor lorlatinib.
Expert Discusses Genomic Testing and Trials Pertinent to Treating Prostate Cancer
During a Targeted Oncology Case-Based Peer Perspectives event, Arash Rezazadeh Kalebasty, MD, discussed genomic testing and evidence-based treatment of a 60-year-old male patient with prostate cancer.
2 Clarke Drive Cranbury, NJ 08512